There’s a life-changing (if not life-saving) drug that is affordable and available over the counter pretty much everywhere in the world. But in this country, it is being sold at more than 5,000 per cent of its production cost.
A few years ago I developed an underactive thyroid: a low level of thyroid hormones (known as T4 and T3) which affects your ability to metabolise food, provide energy to muscles and carry out processes. About 15 in 1,000 women (and 1 in 1,000 men) in Britain suffer from it.
I had lots of symptoms: mysterious weight gain, despite an intense exercise regime and careful diet. I was exhausted and dizzy, several times nearly falling asleep at the wheel. Cuts and injuries failed to heal properly. My periods stopped. I had a total loss of libido and my hair started falling out. I went from being an athletic, energetic mum-of-two to a sluggish, miserable woman
The NHS test for hypothyroidism is to check for a hormone (TSH) that is released by the pituitary gland in response to low thyroid levels. My TSH levels came back normal and I was dismissed by my GP as being “of a certain age” (I was 44). Private blood tests, however, showed that my T4 and T3 levels were extremely low. I went back to my GP with my results and asked for a prescription for T4 (thyroxine) and T3 (liothyronine). My GP prescribed thyroxine with no question. T3, on the other hand, was a no-no.
I soon found out why when I tried to buy liothyronine with my private prescription. It was £1,600 for two months’ supply, and I was probably going to have to take it for the rest of my life. I was devastated. Then I found out that you can buy it overseas for £6 for two months’ supply. I called on friends in Paris and Greece, and they now regularly send me the T3 that I need.
Why is it so expensive here? It turns out that the NHS was being charged a price hike of 5,000 per cent for liothyronine by the drug firm Concordia, now rebranded as Advanz Pharma. It is no longer the only UK supplier but a few weeks ago a report for the Department of Health found evidence that, in spite of national guidance, local healthcare commissioners are refusing to pay for the medication.
My GP still refuses to prescribe it and the price is still prohibitively expensive. Drug firms maintain their stranglehold on the market, and I want to know why.
Fiona McGowan